Tags

Type your tag names separated by a space and hit enter

Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Expert Opin Pharmacother 2009; 10(18):3113-7EO

Abstract

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) was a 25,620 patient study program comparing telmisartan with ramipril or the combination thereof in patients at increased cardiovascular risk. Ramipril had previously been proven to prevent cardiovascular events in a similar population within the HOPE-trial. However, ramipril and other ACE inhibitors (ACE-Is) may have limited tolerability that might restrict their use in patients requiring secondary prevention, whereas angiotensin receptor blockers (ARBs) are suggested to be better tolerated. However, no ARB had been compared with the standard treatment, ramipril, in these cardiovascular patients at increased risk. ONTARGET showed that telmisartan was as effective as ramipril in preventing cardiovascular events, but was better tolerated. The combination of ramipril and telmisartan was not superior to either monotherapy. Taken together, ONTARGET demonstrated that telmisartan is as effective as ramipril in a broad cardiovascular increased-risk population in the middle of the cardiovascular continuum. In these patients who are intolerant to ACE-Is or who do not achieve blood pressure control, the ARB with the best evidence for secondary prevention is telmisartan according to the results of the ONTARGET trial.

Authors+Show Affiliations

University Hospital of the Saarland, Department of Cardiology, Homburg Saar, Germany. magnus@baumhaekel.deNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19925045

Citation

Baumhäkel, Magnus, and Michael Böhm. "Telmisartan Prevents Cardiovascular Events in a Broad Group of At-risk Patients." Expert Opinion On Pharmacotherapy, vol. 10, no. 18, 2009, pp. 3113-7.
Baumhäkel M, Böhm M. Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Expert Opin Pharmacother. 2009;10(18):3113-7.
Baumhäkel, M., & Böhm, M. (2009). Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Expert Opinion On Pharmacotherapy, 10(18), pp. 3113-7. doi:10.1517/14656560903449231.
Baumhäkel M, Böhm M. Telmisartan Prevents Cardiovascular Events in a Broad Group of At-risk Patients. Expert Opin Pharmacother. 2009;10(18):3113-7. PubMed PMID: 19925045.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Telmisartan prevents cardiovascular events in a broad group of at-risk patients. AU - Baumhäkel,Magnus, AU - Böhm,Michael, PY - 2009/11/21/entrez PY - 2009/11/21/pubmed PY - 2010/2/23/medline SP - 3113 EP - 7 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 10 IS - 18 N2 - The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) was a 25,620 patient study program comparing telmisartan with ramipril or the combination thereof in patients at increased cardiovascular risk. Ramipril had previously been proven to prevent cardiovascular events in a similar population within the HOPE-trial. However, ramipril and other ACE inhibitors (ACE-Is) may have limited tolerability that might restrict their use in patients requiring secondary prevention, whereas angiotensin receptor blockers (ARBs) are suggested to be better tolerated. However, no ARB had been compared with the standard treatment, ramipril, in these cardiovascular patients at increased risk. ONTARGET showed that telmisartan was as effective as ramipril in preventing cardiovascular events, but was better tolerated. The combination of ramipril and telmisartan was not superior to either monotherapy. Taken together, ONTARGET demonstrated that telmisartan is as effective as ramipril in a broad cardiovascular increased-risk population in the middle of the cardiovascular continuum. In these patients who are intolerant to ACE-Is or who do not achieve blood pressure control, the ARB with the best evidence for secondary prevention is telmisartan according to the results of the ONTARGET trial. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/19925045/Telmisartan_prevents_cardiovascular_events_in_a_broad_group_of_at_risk_patients_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656560903449231 DB - PRIME DP - Unbound Medicine ER -